The critical role of toll-like receptors - From microbial recognition to autoimmunity: A comprehensive review

Autoimmunity Reviews

Volumn 15, Issue 1, 2016, Pages 1-8

  Jiménez Dalmaroni, Maximiliano Javier ^a   Gerswhin, M Eric ^b   Adamopoulos, Iannis E ^b,c  

^a INSTITUTO DE INVESTIGACIONES BIOQUÍMICAS DE LA PLATA INIBIOLP   (Argentina)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SHRINERS HOSPITALS FOR CHILDREN NORTHERN CALIFORNIA   (United States)

Author keywords

Innate immunity; Osteoclasts; Rheumatoid arthritis; Toll like receptors

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CD14 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HIGH MOBILITY GROUP B1 PROTEIN; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOID DIFFERENTIATION FACTOR 88; OSTEOCLAST DIFFERENTIATION FACTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PATHOGEN ASSOCIATED MOLECULAR PATTERN; PATTERN RECOGNITION RECEPTOR; PROTEIN MD 2; SURFACTANT PROTEIN A; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR; LIGAND;

AMINO TERMINAL SEQUENCE; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELLULAR IMMUNITY; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; CYTOKINE RELEASE; IMMUNE RESPONSE; INNATE IMMUNITY; LIGAND BINDING; MACROPHAGE ACTIVATION; MOLECULAR WEIGHT; OSTEOCLAST; OSTEOCLASTOGENESIS; POINT MUTATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL; UPREGULATION; ANIMAL; ARTHRITIS; COMPARATIVE STUDY; HUMAN; IMMUNOLOGY; MICROBIOLOGY;

ANIMALS; ARTHRITIS; AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS; LIGANDS; SIGNAL TRANSDUCTION; TH17 CELLS; TOLL-LIKE RECEPTORS;

EID: 84952908271     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.08.009     Document Type: Review

References (109)

1. Martinez F.O., Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014, 6:13.
2. Adamopoulos I.E., Mellins E.D. Alternative pathways of osteoclastogenesis in inflammatory arthritis. Nat Rev Rheumatol 2014, 11:189-194.
3. Cavalcante P., Cufi P., Mantegazza R., Berrih-Aknin S., Bernasconi P., Le Panse R. Etiology of myasthenia gravis: innate immunity signature in pathological thymus. Autoimmun Rev 2013, 12:863-874.
4. Cordiglieri C., Marolda R., Franzi S., Cappelletti C., Giardina C., Motta T., et al. Innate immunity in myasthenia gravis thymus: pathogenic effects of Toll-like receptor 4 signaling on autoimmunity. J Autoimmun 2014, 52:74-89.
5. Gianchecchi E., Fierabracci A. Gene/environment interactions in the pathogenesis of autoimmunity: New insights on the role of Toll-like receptors. Autoimmun Rev 2015, 14:971-983.
6. Guerrier T., Pochard P., Lahiri A., Youinou P., Pers J.O., Jamin C. TLR9 expressed on plasma membrane acts as a negative regulator of human B cell response. J Autoimmun 2014, 51:23-29.
7. Konstantinov K.N., Ulff-Moller C.J., Tzamaloukas A.H. Infections and antineutrophil cytoplasmic antibodies: triggering mechanisms. Autoimmun Rev 2015, 14:201-203.
8. Raschi E., Chighizola C.B., Grossi C., Ronda N., Gatti R., Meroni P.L., et al. beta2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. J Autoimmun 2014, 55:42-50.
9. Savic S., Ouboussad L., Dickie L.J., Geiler J., Wong C., Doody G.M., et al. TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes. J Autoimmun 2014, 50:59-66.
10. Vrolix K., Fraussen J., Losen M., Stevens J., Lazaridis K., Molenaar P.C., et al. Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor. J Autoimmun 2014, 52:101-112.
11. Zheng J., Petersen F., Yu X. The role of PTPN22 in autoimmunity: learning from mice. Autoimmun Rev 2014, 13:266-271.
12. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006, 311:1-16.
13. Pandey S., Kawai T., Akira S. Microbial sensing by Toll-like receptors and intracellular nucleic acid sensors. Cold Spring Harb Perspect Biol 2015, 7.
14. Bell J.K., Mullen G.E., Leifer C.A., Mazzoni A., Davies D.R., Segal D.M. Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 2003, 24:528-533.
15. Ozinsky A., Underhill D.M., Fontenot J.D., Hajjar A.M., Smith K.D., Wilson C.B., et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 2000, 97:13766-13771.
16. Jin M.S., Kim S.E., Heo J.Y., Lee M.E., Kim H.M., Paik S.G., et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 2007, 130:1071-1082.
17. Jimenez-Dalmaroni M.J., Radcliffe C.M., Harvey D.J., Wormald M.R., Verdino P., Ainge G.D., et al. Soluble human TLR2 ectodomain binds diacylglycerol from microbial lipopeptides and glycolipids. Innate Immun 2015, 21:175-193.
18. Fournier B., Philpott D.J. Recognition of Staphylococcus aureus by the innate immune system. Clin Microbiol Rev 2005, 18:521-540.
19. Underhill D.M., Ozinsky A., Smith K.D., Aderem A. Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. Proc Natl Acad Sci U S A 1999, 96:14459-14463.
20. Ropert C., Gazzinelli R.T. Regulatory role of Toll-like receptor 2 during infection with Trypanosoma cruzi. J Endotoxin Res 2004, 10:425-430.
21. Govindaraj R.G., Manavalan B., Lee G., Choi S. Molecular modeling-based evaluation of hTLR10 and identification of potential ligands in Toll-like receptor signaling. PLoS One 2010, 5.
22. Nagai Y., Akashi S., Nagafuku M., Ogata M., Iwakura Y., Akira S., et al. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 2002, 3:667-672.
23. Park B.S., Song D.H., Kim H.M., Choi B.S., Lee H., Lee J.O. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009, 458:1191-1195.
24. Hayashi F., Smith K.D., Ozinsky A., Hawn T.R., Yi E.C., Goodlett D.R., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410:1099-1103.
25. Gewirtz A.T., Yu Y., Krishna U.S., Israel D.A., Lyons S.L., Peek R.M. Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate immunity. J Infect Dis 2004, 189:1914-1920.
26. Uematsu S., Jang M.H., Chevrier N., Guo Z., Kumagai Y., Yamamoto M., et al. Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+lamina propria cells. Nat Immunol 2006, 7:868-874.
27. Yoon S.I., Kurnasov O., Natarajan V., Hong M., Gudkov A.V., Osterman A.L., et al. Structural basis of TLR5-flagellin recognition and signaling. Science 2012, 335:859-864.
28. Chattopadhyay S., Sen G.C. dsRNA-activation of TLR3 and RLR signaling: gene induction-dependent and independent effects. J Interferon Cytokine Res 2014, 34:427-436.
29. Wang T., Town T., Alexopoulou L., Anderson J.F., Fikrig E., Flavell R.A. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 2004, 10:1366-1373.
30. Casrouge A., Zhang S.Y., Eidenschenk C., Jouanguy E., Puel A., Yang K., et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006, 314:308-312.
31. Liu Y., Chen H., Sun Y., Chen F. Antiviral role of Toll-like receptors and cytokines against the new 2009 H1N1 virus infection. Mol Biol Rep 2011, 39:1163-1172.
32. Liu L., Botos I., Wang Y., Leonard J.N., Shiloach J., Segal D.M., et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 2008, 320:379-381.
33. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
34. Heil F., Hemmi H., Hochrein H., Ampenberger F., Kirschning C., Akira S., et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004, 303:1526-1529.
35. Tanji H., Ohto U., Shibata T., Miyake K., Shimizu T. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands. Science 2013, 339:1426-1429.
36. Tanji H., Ohto U., Shibata T., Taoka M., Yamauchi Y., Isobe T., et al. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nat Struct Mol Biol 2015, 22:109-115.
37. Medzhitov R., Janeway C.A. Decoding the patterns of self and nonself by the innate immune system. Science 2002, 296:298-300.
38. Seong S.Y., Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 2004, 4:469-478.
39. Taylor K.R., Trowbridge J.M., Rudisill J.A., Termeer C.C., Simon J.C., Gallo R.L. Hyaluronan fragments stimulate endothelial recognition of injury through TLR4. J Biol Chem 2004, 279:17079-17084.
40. Jiang D., Liang J., Fan J., Yu S., Chen S., Luo Y., et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005, 11:1173-1179.
41. Abdollahi-Roodsaz S., Joosten L.A., Roelofs M.F., Radstake T.R., Matera G., Popa C., et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 2007, 56:2957-2967.
42. Papathanasiou I., Malizos K.N., Poultsides L., Karachalios T., Oikonomou P., Tsezou A. The catabolic role of toll-like receptor 2 (TLR-2) mediated by the NF-kappaB pathway in septic arthritis. J Orthop Res 2011, 29:247-251.
43. Guiducci C., Gong M., Cepika A.M., Xu Z., Tripodo C., Bennett L., et al. RNA recognition by human TLR8 can lead to autoimmune inflammation. J Exp Med 2013, 210:2903-2919.
44. Adamopoulos I.E., Sabokbar A., Wordsworth B.P., Carr A., Ferguson D.J., Athanasou N.A. Synovial fluid macrophages are capable of osteoclast formation and resorption. J Pathol 2006, 208:35-43.
45. Adamopoulos I.E., Danks L., Itonaga I., Locklin R.M., Sabokbar A., Ferguson D.J., et al. Stimulation of osteoclast formation by inflammatory synovial fluid. Virchows Arch 2006, 449:69-77.
46. Rivollier A., Mazzorana M., Tebib J., Piperno M., Aitsiselmi T., Rabourdin-Combe C., et al. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 2004, 104:4029-4037.
47. Vabulas R.M., Ahmad-Nejad P., Ghose S., Kirschning C.J., Issels R.D., Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002, 277:15107-15112.
48. Sato M., Sano H., Iwaki D., Kudo K., Konishi M., Takahashi H., et al. Direct binding of Toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A. J Immunol 2003, 171:417-425.
49. Park J.S., Svetkauskaite D., He Q., Kim J.Y., Strassheim D., Ishizaka A., et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004, 279:7370-7377.
50. Jana M., Palencia C.A., Pahan K. Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer's disease. J Immunol 2008, 181:7254-7262.
51. Balogh S., Kiss I., Csaszar A. Toll-like receptors: link between "danger" ligands and plaque instability. Curr Drug Targets 2009, 10:513-518.
52. Guiducci C., Gong M., Xu Z., Gill M., Chaussabel D., Meeker T., et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010, 465:937-941.
53. Feldman N., Rotter A., Okun E. DAMPs as mediators of sterile inflammation in aging-related pathologies. Ageing Res Rev 2015, (Epub ahead of print, pii: S1568-1637(15)00005-7). 10.1016/j.arr.2015.01.003.
54. Piccinini A.M., Midwood K.S. DAMPening inflammation by modulating TLR signalling. Mediat Inflamm 2010, 2010.
55. Tsan M.F., Gao B. Pathogen-associated molecular pattern contamination as putative endogenous ligands of Toll-like receptors. J Endotoxin Res 2007, 13:6-14.
56. Kim Y.M., Brinkmann M.M., Paquet M.E., Ploegh H.L. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 2008, 452:234-238.
57. Fukui R., Saitoh S., Kanno A., Onji M., Shibata T., Ito A., et al. Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking. Immunity 2011, 35:69-81.
58. Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y.H., Homey B., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449:564-569.
59. Ganguly D., Chamilos G., Lande R., Gregorio J., Meller S., Facchinetti V., et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009, 206:1983-1994.
60. Lai Y., Adhikarakunnathu S., Bhardwaj K., Ranjith-Kumar C.T., Wen Y., Jordan J.L., et al. LL37 and cationic peptides enhance TLR3 signaling by viral double-stranded RNAs. PLoS One 2011, 6.
61. Park B., Buti L., Lee S., Matsuwaki T., Spooner E., Brinkmann M.M., et al. Granulin is a soluble cofactor for toll-like receptor 9 signaling. Immunity 2011, 34:505-513.
62. Moresco E.M., Beutler B. Special delivery: granulin brings CpG DNA to Toll-like receptor 9. Immunity 2011, 34:453-455.
63. Jiang Z., Georgel P., Du X., Shamel L., Sovath S., Mudd S., et al. CD14 is required for MyD88-independent LPS signaling. Nat Immunol 2005, 6:565-570.
64. Nakata T., Yasuda M., Fujita M., Kataoka H., Kiura K., Sano H., et al. CD14 directly binds to triacylated lipopeptides and facilitates recognition of the lipopeptides by the receptor complex of Toll-like receptors 2 and 1 without binding to the complex. Cell Microbiol 2006, 8:1899-1909.
65. Jimenez-Dalmaroni M.J., Xiao N., Corper A.L., Verdino P., Ainge G.D., Larsen D.S., et al. Soluble CD36 Ectodomain Binds Negatively Charged Diacylglycerol Ligands and Acts as a Co-Receptor for TLR2. PLoS One 2009, 4.
66. Hoebe K., Georgel P., Rutschmann S., Du X., Mudd S., Crozat K., et al. CD36 is a sensor of diacylglycerides. Nature 2005, 433:523-527.
67. Stewart C.R., Stuart L.M., Wilkinson K., van Gils J.M., Deng J., Halle A., et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2009, 11:155-161.
68. Sheedy F.J., Grebe A., Rayner K.J., Kalantari P., Ramkhelawon B., Carpenter S.B., et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation. Nat Immunol 2013, 14:812-820.
69. Neculai D., Schwake M., Ravichandran M., Zunke F., Collins R.F., Peters J., et al. Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36. Nature 2013, 504:172-176.
70. Kelley S.L., Lukk T., Nair S.K., Tapping R.I. The crystal structure of human soluble CD14 reveals a bent solenoid with a hydrophobic amino-terminal pocket. J Immunol 2012, 190:1304-1311.
71. Zanoni I., Ostuni R., Marek L.R., Barresi S., Barbalat R., Barton G.M., et al. CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. Cell 2011, 147:868-880.
72. Itoh K., Udagawa N., Kobayashi K., Suda K., Li X., Takami M., et al. Lipopolysaccharide promotes the survival of osteoclasts via Toll-like receptor 4, but cytokine production of osteoclasts in response to lipopolysaccharide is different from that of macrophages. J Immunol 2003, 170:3688-3695.
73. O'Neill L.A., Bowie A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007, 7:353-364.
74. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004, 430:257-263.
75. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434:772-777.
76. Barton G.M., Medzhitov R. Toll-like receptor signaling pathways. Science 2003, 300:1524-1525.
77. Ji J.D., Park-Min K.H., Shen Z., Fajardo R.J., Goldring S.R., McHugh K.P., et al. Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors. J Immunol 2009, 183:7223-7233.
78. Takami M., Kim N., Rho J., Choi Y. Stimulation by toll-like receptors inhibits osteoclast differentiation. J Immunol 2002, 169:1516-1523.
79. Kim K.W., Cho M.L., Oh H.J., Kim H.R., Kang C.M., Heo Y.M., et al. TLR-3 enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis. Immunol Lett 2009, 124:9-17.
80. Bar-Shavit Z. Taking a toll on the bones: regulation of bone metabolism by innate immune regulators. Autoimmunity 2008, 41:195-203.
81. Hayashi S., Tsuneto M., Yamada T., Nose M., Yoshino M., Shultz L.D., et al. Lipopolysaccharide-induced osteoclastogenesis in Src homology 2-domain phosphatase-1-deficient viable motheaten mice. Endocrinology 2004, 145:2721-2729.
82. Krisher T., Bar-Shavit Z. Regulation of osteoclastogenesis by integrated signals from toll-like receptors. J Cell Biochem 2014, 115:2146-2154.
83. Liew F.Y., Xu D., Brint E.K., O'Neill L.A. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005, 5:446-458.
84. LeBouder E., Rey-Nores J.E., Rushmere N.K., Grigorov M., Lawn S.D., Affolter M., et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol 2003, 171:6680-6689.
85. Raby A.C., Le Bouder E., Colmont C., Davies J., Richards P., Coles B., et al. Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. J Immunol 2009, 183:506-517.
86. Oosting M., Cheng S.C., Bolscher J.M., Vestering-Stenger R., Plantinga T.S., Verschueren I.C., et al. Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proc Natl Acad Sci U S A 2014, 111:E4478-E4484.
87. Zielinski C.E., Mele F., Aschenbrenner D., Jarrossay D., Ronchi F., Gattorno M., et al. Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta. Nature 2012, 484:514-518.
88. Sallusto F., Lanzavecchia A. Human Th17 cells in infection and autoimmunity. Microbes Infect 2009, 11:620-624.
89. Saba R., Sorensen D.L., Booth S.A. MicroRNA-146a: a dominant, negative regulator of the innate immune response. Front Immunol 2014, 5:578.
90. Philippe L., Alsaleh G., Suffert G., Meyer A., Georgel P., Sibilia J., et al. TLR2 expression is regulated by microRNA miR-19 in rheumatoid fibroblast-like synoviocytes. J Immunol 2011, 188:454-461.
91. Galicia J.C., Naqvi A.R., Ko C.C., Nares S., Khan A.A. MiRNA-181a regulates Toll-like receptor agonist-induced inflammatory response in human fibroblasts. Genes Immun 2014, 15:333-337.
92. Fabbri M., Paone A., Calore F., Galli R., Gaudio E., Santhanam R., et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 2012, 109:E2110-E2116.
93. Mills K.H. TLR-dependent T, cell activation in autoimmunity. Nat Rev Immunol 2011, 11:807-822.
94. Sweet R.A., Cullen J.L., Shlomchik M.J. Rheumatoid factor B cell memory leads to rapid, switched antibody-forming cell responses. J Immunol 2013, 190:1974-1981.
95. Pisitkun P., Deane J.A., Difilippantonio M.J., Tarasenko T., Satterthwaite A.B., Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006, 312:1669-1672.
96. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416:603-607.
97. Vogelpoel L.T., Hansen I.S., Rispens T., Muller F.J., van Capel T.M., Turina M.C., et al. Fc gamma receptor-TLR cross-talk elicits pro-inflammatory cytokine production by human M2 macrophages. Nat Commun 2014, 5:5444.
98. Vogelpoel L.T., Hansen I.S., Visser M.W., Nagelkerke S.Q., Kuijpers T.W., Kapsenberg M.L., et al. FcgammaRIIa cross-talk with TLRs, IL-1R, and IFNgammaR selectively modulates cytokine production in human myeloid cells. Immunobiology 2014, 220:193-199.
99. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673-2682.
100. Akbal A., Oguz S., Gokmen F., Bilim S., Resorlu H., Silan F., et al. C-reactive protein gene and Toll-like receptor 4 gene polymorphisms can relate to the development of psoriatic arthritis. Clin Rheumatol 2014, 34:301-306.
101. Lee S.M., Kok K.H., Jaume M., Cheung T.K., Yip T.F., Lai J.C., et al. Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection. Proc Natl Acad Sci U S A 2014, 111:3793-3798.
102. Davis M.L., LeVan T.D., Yu F., Sayles H., Sokolove J., Robinson W., et al. Associations of toll-like receptor (TLR)-4 single nucleotide polymorphisms and rheumatoid arthritis disease progression: An observational cohort study. Int Immunopharmacol 2015, 24:346-352.
103. Popa C., Abdollahi-Roodsaz S., Joosten L.A., Takahashi N., Sprong T., Matera G., et al. Bartonella quintana lipopolysaccharide is a natural antagonist of Toll-like receptor 4. Infect Immun 2007, 75:4831-4837.
104. Pawar R.D., Ramanjaneyulu A., Kulkarni O.P., Lech M., Segerer S., Anders H.J. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007, 18:1721-1731.
105. Bartfai T., Behrens M.M., Gaidarova S., Pemberton J., Shivanyuk A., Rebek J. A low molecular weight mimic of the Toll/IL-1 receptor/resistance domain inhibits IL-1 receptor-mediated responses. Proc Natl Acad Sci U S A 2003, 100:7971-7976.
106. Poblenz A.T., Jacoby J.J., Singh S., Darnay B.G. Inhibition of RANKL-mediated osteoclast differentiation by selective TRAF6 decoy peptides. Biochem Biophys Res Commun 2007, 359:510-515.
107. Romagne F. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. Drug Discov Today 2007, 12:80-87.
108. Chatzigeorgiou A., Seijkens T., Zarzycka B., Engel D., Poggi M., van den Berg S., et al. Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance. Proc Natl Acad Sci U S A 2014, 111:2686-2691.
109. Bernstein F.C., Koetzle T.F., Williams G.J., Meyer E.F., Brice M.D., Rodgers J.R., et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol 1977, 112:535-542.